$BNGO
Bionano Genomics, Inc.

2021 Q1 Form 10-Q Financial Statement

#000141169021000014 Filed on May 13, 2021

View on sec.gov

Income Statement

Concept 2021 Q1 2020 Q1
Revenue $3.168M $1.136M
YoY Change 178.87% -38.69%
Cost Of Revenue $2.125M $856.0K
YoY Change 148.25% -25.37%
Gross Profit $1.043M $280.0K
YoY Change 272.5% -60.34%
Gross Profit Margin 32.92% 24.65%
Selling, General & Admin $9.528M $7.368M
YoY Change 29.32% 53.79%
% of Gross Profit 913.52% 2631.43%
Research & Development $2.678M $2.674M
YoY Change 0.15% 27.33%
% of Gross Profit 256.76% 955.0%
Depreciation & Amortization $448.0K $296.0K
YoY Change 51.35% 9.63%
% of Gross Profit 42.95% 105.71%
Operating Expenses $12.21M $10.04M
YoY Change 21.55% 45.73%
Operating Profit -$11.16M -$9.762M
YoY Change 14.35% 57.83%
Interest Expense $600.0K $761.0K
YoY Change -21.16% 178.75%
% of Operating Profit
Other Income/Expense, Net $1.222M -$743.0K
YoY Change -264.47% -55.29%
Pretax Income -$9.941M -$10.51M
YoY Change -5.37% 33.87%
Income Tax $6.000K $5.000K
% Of Pretax Income
Net Earnings -$9.947M -$10.51M
YoY Change -5.36% 33.85%
Net Earnings / Revenue -313.98% -925.18%
Basic Earnings Per Share -$0.04
Diluted Earnings Per Share -$0.04 -$295.5K
COMMON SHARES
Basic Shares Outstanding 263.9M shares 37.75M shares
Diluted Shares Outstanding 263.9M shares

Balance Sheet

Concept 2021 Q1 2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $362.1M $8.100M
YoY Change 4370.37% -61.06%
Cash & Equivalents $362.1M $8.144M
Short-Term Investments
Other Short-Term Assets $3.200M $1.100M
YoY Change 190.91% -19.94%
Inventory $3.036M $3.611M
Prepaid Expenses
Receivables $1.992M $4.115M
Other Receivables $0.00 $0.00
Total Short-Term Assets $370.3M $16.98M
YoY Change 2080.26% -39.38%
LONG-TERM ASSETS
Property, Plant & Equipment $5.806M $2.120M
YoY Change 173.87% 37.92%
Goodwill $7.173M
YoY Change
Intangibles $1.396M
YoY Change
Long-Term Investments
YoY Change
Other Assets $235.0K
YoY Change
Total Long-Term Assets $14.61M $2.120M
YoY Change 589.15% 37.92%
TOTAL ASSETS
Total Short-Term Assets $370.3M $16.98M
Total Long-Term Assets $14.61M $2.120M
Total Assets $384.9M $19.10M
YoY Change 1914.77% -35.36%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.209M $3.176M
YoY Change -30.45% 264.71%
Accrued Expenses $4.659M $2.725M
YoY Change 70.97% -24.91%
Deferred Revenue $301.0K $318.0K
YoY Change -5.35%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $16.97M
YoY Change
Total Short-Term Liabilities $7.169M $23.19M
YoY Change -69.08% 391.95%
LONG-TERM LIABILITIES
Long-Term Debt $14.87M $0.00
YoY Change -100.0%
Other Long-Term Liabilities $100.0K $0.00
YoY Change -100.0%
Total Long-Term Liabilities $14.87M $0.00
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $7.169M $23.19M
Total Long-Term Liabilities $14.87M $0.00
Total Liabilities $22.14M $23.32M
YoY Change -5.03% -1.55%
SHAREHOLDERS EQUITY
Retained Earnings -$153.6M -$113.1M
YoY Change 35.85% 40.28%
Common Stock $516.3M $108.9M
YoY Change 374.26% 25.89%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $362.7M -$4.213M
YoY Change
Total Liabilities & Shareholders Equity $384.9M $19.10M
YoY Change 1914.77% -35.36%

Cashflow Statement

Concept 2021 Q1 2020 Q1
OPERATING ACTIVITIES
Net Income -$9.947M -$10.51M
YoY Change -5.36% 33.85%
Depreciation, Depletion And Amortization $448.0K $296.0K
YoY Change 51.35% 9.63%
Cash From Operating Activities -$13.90M -$8.032M
YoY Change 73.11% 22.59%
INVESTING ACTIVITIES
Capital Expenditures $24.00K $0.00
YoY Change
Acquisitions $0.00
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$24.00K $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $328.6M $0.00
YoY Change -100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $337.5M -$1.135M
YoY Change -29838.85% -110.45%
NET CHANGE
Cash From Operating Activities -$13.90M -$8.032M
Cash From Investing Activities -$24.00K $0.00
Cash From Financing Activities $337.5M -$1.135M
Net Change In Cash $323.6M -$9.167M
YoY Change -3630.14% -312.84%
FREE CASH FLOW
Cash From Operating Activities -$13.90M -$8.032M
Capital Expenditures $24.00K $0.00
Free Cash Flow -$13.93M -$8.032M
YoY Change 73.41% 22.59%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q1 dei Amendment Flag
AmendmentFlag
false
CY2021Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2021Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001411690
CY2021Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021Q1 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P9M
CY2021Q1 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P1Y
CY2021Q1 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P1Y
CY2021Q1 dei Document Type
DocumentType
10-Q
CY2021Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2021Q1 dei Document Period End Date
DocumentPeriodEndDate
2021-03-31
CY2021Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2021Q1 dei Entity File Number
EntityFileNumber
001-38613
CY2021Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021Q1 dei Local Phone Number
LocalPhoneNumber
888-7600
CY2021Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
CY2021Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2021Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92121
CY2021Q1 dei City Area Code
CityAreaCode
858
CY2021Q1 dei Entity Registrant Name
EntityRegistrantName
Bionano Genomics, Inc.
CY2021Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
26-1756290
CY2021Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
9540 Towne Centre Drive, Suite 100
CY2021Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2021Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2021Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2021Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2021Q1 dei Entity Shell Company
EntityShellCompany
false
CY2021Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
278849616 shares
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
362057000 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
38449000 USD
CY2021Q1 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
2091000 USD
CY2020Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
2119000 USD
CY2021Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1992000 USD
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2775000 USD
CY2021Q1 us-gaap Inventory Net
InventoryNet
3036000 USD
CY2020Q4 us-gaap Inventory Net
InventoryNet
3316000 USD
CY2021Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3166000 USD
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2250000 USD
CY2021Q1 us-gaap Assets Current
AssetsCurrent
370251000 USD
CY2020Q4 us-gaap Assets Current
AssetsCurrent
46790000 USD
CY2021Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5806000 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4910000 USD
CY2021Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1396000 USD
CY2020Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1475000 USD
CY2020Q4 us-gaap Assets
Assets
60451000 USD
CY2021Q1 us-gaap Goodwill
Goodwill
7173000 USD
CY2020Q4 us-gaap Goodwill
Goodwill
7173000 USD
CY2021Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
235000 USD
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
103000 USD
CY2021Q1 us-gaap Assets
Assets
384861000 USD
CY2021Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
2209000 USD
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2930000 USD
CY2021Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4659000 USD
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5599000 USD
CY2021Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
301000 USD
CY2020Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
416000 USD
CY2021Q1 us-gaap Liabilities Current
LiabilitiesCurrent
7169000 USD
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
8945000 USD
CY2021Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
14866000 USD
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
16326000 USD
CY2021Q1 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
108000 USD
CY2020Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
98000 USD
CY2021Q1 us-gaap Liabilities
Liabilities
22143000 USD
CY2020Q4 us-gaap Liabilities
Liabilities
25369000 USD
CY2021Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2021Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2021Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000 shares
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000 shares
CY2021Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
278794000 shares
CY2021Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
278794000 shares
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
189953000 shares
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
189953000 shares
CY2021Q1 us-gaap Common Stock Value
CommonStockValue
28000 USD
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
19000 USD
CY2021Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
516321000 USD
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
178747000 USD
CY2021Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-153631000 USD
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-143684000 USD
CY2021Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
263939000 shares
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
362718000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
35082000 USD
CY2021Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
384861000 USD
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
60451000 USD
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3168000 USD
CY2020Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1136000 USD
CY2021Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2125000 USD
CY2020Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
856000 USD
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2678000 USD
CY2020Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2674000 USD
CY2021Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
9528000 USD
CY2020Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
7368000 USD
CY2021Q1 us-gaap Costs And Expenses
CostsAndExpenses
12206000 USD
CY2020Q1 us-gaap Costs And Expenses
CostsAndExpenses
10042000 USD
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-11163000 USD
CY2020Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-9762000 USD
CY2021Q1 us-gaap Interest Expense
InterestExpense
538000 USD
CY2020Q1 us-gaap Interest Expense
InterestExpense
761000 USD
CY2021Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
1775000 USD
CY2020Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 USD
CY2021Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-15000 USD
CY2020Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
18000 USD
CY2021Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1222000 USD
CY2020Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-743000 USD
CY2021Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-9941000 USD
CY2020Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-10505000 USD
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
6000 USD
CY2020Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
5000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-9947000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-10510000 USD
CY2021Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.04
CY2020Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.30
CY2020Q1 bngo Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
2355000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-10510000 USD
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
-4213000 USD
CY2020Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
35569000 shares
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
3614000 USD
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
328000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
35082000 USD
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
333000 USD
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
371000 USD
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
327486000 USD
CY2021Q1 bngo Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
9393000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-9947000 USD
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
362718000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-9947000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-10510000 USD
CY2021Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
448000 USD
CY2020Q1 us-gaap Paid In Kind Interest
PaidInKindInterest
379000 USD
CY2021Q1 us-gaap Paid In Kind Interest
PaidInKindInterest
315000 USD
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
371000 USD
CY2020Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
296000 USD
CY2020Q1 us-gaap Share Based Compensation
ShareBasedCompensation
328000 USD
CY2021Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
0 USD
CY2020Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
958000 USD
CY2021Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
1775000 USD
CY2020Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 USD
CY2021Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-783000 USD
CY2020Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-1261000 USD
CY2021Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
961000 USD
CY2020Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
635000 USD
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1049000 USD
CY2020Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-53000 USD
CY2021Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1045000 USD
CY2020Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
477000 USD
CY2021Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-1044000 USD
CY2020Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-639000 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-13904000 USD
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8032000 USD
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
24000 USD
CY2020Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-24000 USD
CY2020Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 USD
CY2021Q1 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
0 USD
CY2020Q1 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
2100000 USD
CY2021Q1 us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
0 USD
CY2020Q1 us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
761000 USD
CY2021Q1 us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
0 USD
CY2020Q1 us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
2156000 USD
CY2021Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
328635000 USD
CY2021Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
825000 USD
CY2020Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 USD
CY2020Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0 USD
CY2021Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
9726000 USD
CY2020Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2360000 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
337536000 USD
CY2020Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-1135000 USD
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
323608000 USD
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-9167000 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
38449000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
17311000 USD
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
362057000 USD
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8144000 USD
CY2021Q1 us-gaap Interest Paid Net
InterestPaidNet
287000 USD
CY2020Q1 us-gaap Interest Paid Net
InterestPaidNet
382000 USD
CY2021Q1 bngo Transfer Of Instruments And Servers From Property And Equipment Into Inventory
TransferOfInstrumentsAndServersFromPropertyAndEquipmentIntoInventory
126000 USD
CY2020Q1 bngo Transfer Of Instruments And Servers From Property And Equipment Into Inventory
TransferOfInstrumentsAndServersFromPropertyAndEquipmentIntoInventory
0 USD
CY2021Q1 bngo Transfer Of Instruments And Servers To Property And Equipment From Inventory
TransferOfInstrumentsAndServersToPropertyAndEquipmentFromInventory
1366000 USD
CY2020Q1 bngo Transfer Of Instruments And Servers To Property And Equipment From Inventory
TransferOfInstrumentsAndServersToPropertyAndEquipmentFromInventory
467000 USD
CY2021Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
1775000 USD
CY2020Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 USD
CY2021Q1 bngo Offering Costs Incurred Not Yet Paid
OfferingCostsIncurredNotYetPaid
324000 USD
CY2020Q1 bngo Offering Costs Incurred Not Yet Paid
OfferingCostsIncurredNotYetPaid
0 USD
CY2021Q1 bngo Warrant Exercise Non Cash
WarrantExerciseNonCash
129000 USD
CY2020Q1 bngo Warrant Exercise Non Cash
WarrantExerciseNonCash
0 USD
CY2020Q1 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
127000 USD
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
362100000 USD
CY2021Q1 bngo Working Capital
WorkingCapital
363100000 USD
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9537000 shares
CY2020Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
26888000 shares
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3168000 USD
CY2020Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1136000 USD
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3168000 USD
CY2020Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1136000 USD
CY2021Q1 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
409000 USD
CY2021Q1 us-gaap Revenue Remaining Performance Obligation Percentage
RevenueRemainingPerformanceObligationPercentage
0.648
CY2021Q1 us-gaap Revenue Remaining Performance Obligation Percentage
RevenueRemainingPerformanceObligationPercentage
0.311
CY2021Q1 us-gaap Revenue Remaining Performance Obligation Percentage
RevenueRemainingPerformanceObligationPercentage
0.041
CY2021Q1 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
156885 USD
CY2021Q1 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
4083000 USD
CY2020Q4 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
4894000 USD
CY2021Q1 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
2091000 USD
CY2020Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
2119000 USD
CY2021Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1992000 USD
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2775000 USD
CY2021Q1 us-gaap Allowance For Doubtful Accounts Receivable Recoveries
AllowanceForDoubtfulAccountsReceivableRecoveries
28000 USD
CY2021Q1 us-gaap Inventory Raw Materials And Supplies Net Of Reserves
InventoryRawMaterialsAndSuppliesNetOfReserves
2736000 USD
CY2020Q4 us-gaap Inventory Raw Materials And Supplies Net Of Reserves
InventoryRawMaterialsAndSuppliesNetOfReserves
2283000 USD
CY2021Q1 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
300000 USD
CY2020Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
1033000 USD
CY2021Q1 us-gaap Inventory Net
InventoryNet
3036000 USD
CY2020Q4 us-gaap Inventory Net
InventoryNet
3316000 USD
CY2021Q1 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
16099000 USD
CY2020Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
17756000 USD
CY2021Q1 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
6298152 shares
CY2021Q1 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
38333352 shares
CY2021Q1 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
6.00
CY2021Q1 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
1233000 USD
CY2020Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
1430000 USD
CY2021Q1 us-gaap Long Term Debt
LongTermDebt
14866000 USD
CY2020Q4 us-gaap Long Term Debt
LongTermDebt
16326000 USD
CY2021Q1 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
33368851 shares
CY2021Q1 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
3.05
CY2021Q1 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
101800000 USD
CY2021Q1 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
293000 USD
CY2021Q1 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
230000000.0 USD
CY2021Q1 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
435000 USD
CY2020Q3 bngo Sale Of Stock Authorized Amount To Be Issued
SaleOfStockAuthorizedAmountToBeIssued
125000000.0 USD
CY2021Q1 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
27025384 shares
CY2020Q4 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
0.82
CY2021Q1 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
22100000 USD
CY2020Q4 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
573000 USD
CY2021Q1 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
2.68
CY2021Q1 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
16900000 USD
CY2021Q1 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
422000 USD
CY2020Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
15174000 shares
CY2020Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
2.34
CY2020 bngo Class Of Warrant Or Right Weighted Average Remaining Contractual Term Of Warrants Or Rights
ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRights
P3Y9M3D
CY2020Q4 bngo Class Of Warrant Or Right Aggregate Intrinsic Value Of Warrants Or Rights
ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRights
26841000 USD
CY2021Q1 bngo Class Of Warrant Or Right Number Of Securities Granted In Period
ClassOfWarrantOrRightNumberOfSecuritiesGrantedInPeriod
0 shares
CY2021Q1 bngo Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Granted In Period
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGrantedInPeriod
CY2021Q1 bngo Class Of Warrant Or Right Weighted Average Remaining Contractual Term Granted In Period Of Warrants Or Rights
ClassOfWarrantOrRightWeightedAverageRemainingContractualTermGrantedInPeriodOfWarrantsOrRights
CY2021Q1 bngo Class Of Warrant Or Right Number Of Securities Exercised In Period
ClassOfWarrantOrRightNumberOfSecuritiesExercisedInPeriod
10739000 shares
CY2021Q1 bngo Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Exercised In Period
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercisedInPeriod
0.89
CY2021Q1 bngo Class Of Warrant Or Right Aggregate Intrinsic Value Exercised In Period Of Warrants Or Rights
ClassOfWarrantOrRightAggregateIntrinsicValueExercisedInPeriodOfWarrantsOrRights
57912000 USD
CY2021Q1 bngo Class Of Warrant Or Right Number Of Securities Canceled In Period
ClassOfWarrantOrRightNumberOfSecuritiesCanceledInPeriod
24000 shares
CY2021Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
4411000 shares
CY2021Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
5.89
CY2021Q1 bngo Class Of Warrant Or Right Weighted Average Remaining Contractual Term Of Warrants Or Rights
ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRights
P2Y6M
CY2021Q1 bngo Class Of Warrant Or Right Aggregate Intrinsic Value Of Warrants Or Rights
ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRights
2911000 USD
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5290000 shares
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.91
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y8M12D
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
10178000 USD
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
138000 shares
CY2021Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
10.83
CY2021Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
102000 shares
CY2021Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
3.28
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
1153000 USD
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
10.83
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
200000 shares
CY2021Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0.97
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5126000 shares
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.16
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y7M28D
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
31554000 USD
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
1704000 shares
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
3.62
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P8Y7D
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
8403000 USD
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.04
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
371000 USD
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
328000 USD
CY2020Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.007
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.014
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.793
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.700
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y1M6D
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
CY2021Q1 us-gaap Business Acquisition Pro Forma Earnings Per Share Diluted
BusinessAcquisitionProFormaEarningsPerShareDiluted
-0.28
CY2021Q1 us-gaap Business Acquisition Pro Forma Earnings Per Share Basic
BusinessAcquisitionProFormaEarningsPerShareBasic
-0.28

Files In Submission

Name View Source Status
0001411690-21-000014-index-headers.html Edgar Link pending
0001411690-21-000014-index.html Edgar Link pending
0001411690-21-000014.txt Edgar Link pending
0001411690-21-000014-xbrl.zip Edgar Link pending
bngo-20210331.htm Edgar Link pending
bngo-20210331.xsd Edgar Link pending
bngo-20210331xexx311.htm Edgar Link pending
bngo-20210331xexx312.htm Edgar Link pending
bngo-20210331xexx321.htm Edgar Link pending
bngo-20210331_cal.xml Edgar Link unprocessable
bngo-20210331_def.xml Edgar Link unprocessable
bngo-20210331_htm.xml Edgar Link completed
bngo-20210331_lab.xml Edgar Link unprocessable
bngo-20210331_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending